in vivo data before tweaking in vitro [Dissolution / BCS / IVIVC]

posted by Helmut Homepage – Vienna, Austria, 2017-06-24 21:30 (3277 d 07:53 ago) – Posting: # 17501
Views: 9,810

Hi Kiran,

a generic product must demonstrate BE in the rate (Cmax) and extent of absorption (AUC), right?
If your dissolution method is not predictive (you can’t tell before you have in vivo data!) any difference might – or might not – be relevant.
Run a small pilot study to get an idea. IMHO, it is a waste of time to first tweak the dissolution which possibly was overdiscriminatory.
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
161 visitors (0 registered, 161 guests [including 28 identified bots]).
Forum time: 05:24 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5